Patents by Inventor Grégoire Petitjean

Grégoire Petitjean has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prevention of the risks associated with drug-induced QT interval prolongation by using a specific inhibitor of the production of ROS of miochondrial origin
    Patent number: 11554106
    Abstract: A method of treating a subject for reducing the risk of QT space prolongation associated with the intake of a drug known to prolong QT space includes administering to the subject at least one specific inhibitor of mitochondrial ROS production selected from among anethole trithione (ATT), 4-OH-anethole trithione (ATX), and an ATX ester, and administering to the subject the drug known to prolong QT space.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: January 17, 2023
    Inventors: Marc Childs, Jacque Sauzieres, Olivier Petitjean, Guillaume Petitjean, Elodie Petitjean, Grégoire Petitjean
  • PREVENTION OF THE RISKS ASSOCIATED WITH DRUG-INDUCED QT INTERVAL PROLONGATION BY USING A SPECIFIC INHIBITOR OF THE PRODUCTION OF ROS OF MIOCHONDRIAL ORIGIN
    Publication number: 20210052549
    Abstract: A method of treating a subject for reducing the risk of QT space prolongation associated with the intake of a drug known to prolong QT space includes administering to the subject at least one specific inhibitor of mitochondrial ROS production selected from among anethole trithione (ATT), 4-OH-anethole trithione (ATX), and an ATX ester, and administering to the subject the drug known to prolong QT space.
    Type: Application
    Filed: March 7, 2018
    Publication date: February 25, 2021
    Inventors: Marc Childs, Jacque Sauzieres, Olivier Petitjean, Guillaume Petitjean, Elodie Petitjean, Grégoire Petitjean